GO
Loading...

Biotechnology

More

  • Biotech Buyouts & Deal Flows     Friday, 20 Jan 2012 | 4:25 PM ET

    The biotech industry is off to its best start in over a decade. What's driving the accelerated growth? CNBC's Seema Mody has the details on speculative buyout targets this year.

  • Cramer's Speculative Biotech Play: Regeneron     Tuesday, 10 Jan 2012 | 6:15 PM ET

    Len Schleifer, Regeneron Pharmaceuticals CEO, discusses smart biotech investing and growth prospects in the company's pipeline, with Mad Money's Jim Cramer.

  • SGEN's Adcetris Targets Lymphomas     Tuesday, 10 Jan 2012 | 5:34 PM ET

    Clay Siegall, Seattle Genetics president & CEO, discusses the company's cancer drug, Adcetris, and which new drugs are in the company's pipeline for 2012.

  • Vertex & Biogen CEOs Talk Business     Tuesday, 10 Jan 2012 | 4:38 PM ET

    Jeffrey Leiden, Vertex Incoming CEO, and George Scangos, Biogen Idec CEO, discuss Biogen's restructuring and Vertex's Hepatitis C drug.

  • Which Biotech Company Is the Next Takeover Target? Monday, 9 Jan 2012 | 5:52 PM ET

    As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?

  • Health Care & the State of Biotech     Monday, 9 Jan 2012 | 5:19 PM ET

    Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates.

  • 2011 Top Stocks: No. 5 Biogen Idec Wednesday, 28 Dec 2011 | 2:59 PM ET

    The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.

  • Fab Four: Biotech Stocks in 2012     Wednesday, 21 Dec 2011 | 1:44 PM ET

    The biotech sector has surged more than 9% in 2011, so what should investors expect for the new year? Chris Raymond, Robert W. Baird senior biotech analyst, and Karen Anderson, Morningstar senior equity analyst share insight into the sector.

  • Bulls Seek Major Rebound From Targacept Tuesday, 13 Dec 2011 | 6:02 AM ET

    Targacept has been exiled to the woodshed, but yesterday the buyers came back in force.

  • Questcor: A Cheap Biotech Stock Thursday, 17 Nov 2011 | 6:55 PM ET

    Cramer goes one-on-one with Questcor CEO Don Bailey to find out more about the company.

  • Biotech Down Big     Tuesday, 8 Nov 2011 | 2:35 PM ET

    Analysis on why the biotech sector is seeing a down trend, with Raghuram Selvaraju, Morgan Joseph TriArtisan senior vice-president/senior biotechnology analyst.

  • ImmunoGen CEO on New Breast Cancer Drug Monday, 26 Sep 2011 | 6:49 PM ET

    Daniel Junius talks to Cramer about the drug’s recent trial, which was good news for the company’s stock, and when the FDA could get it for approval.

  • ImmunoGen Gets Positive Data on New Drug     Monday, 26 Sep 2011 | 6:48 PM ET

    In this volatile market, investors need stocks that will keep them interested even when things are at their most bleak, says Mad Money host, Jim Cramer. Discussing the next-generation of cancer treatments with biotech developer, Daniel Julies, ImmunoGen CEO.

  • Cramer makes the call on viewers' favorite stocks.

  • Herb on the Street: Dendreon     Thursday, 4 Aug 2011 | 9:37 AM ET

    CNBC's Herb Greenberg reports the biotech company missed sales guidance in a big way.

  • Biogen: An Impressive Turnaround?     Tuesday, 26 Jul 2011 | 3:40 PM ET

    Discussing whether the company's restructuring efforts has paid off, and its ability to compete in the big pharma space, with George Scangos, Biogen CEO.

  • Cramer makes the call on viewers' favorite stocks.

  • Actelion Will Stay Independent: Founder Thursday, 21 Jul 2011 | 1:49 AM ET

    The chief executive and founder of Actelion, one of the world's biggest biotechnology companies, said the firm would stay independent despite pressure from activist shareholders.

  • Cramer Interviews Celgene CEO Hugin Thursday, 30 Jun 2011 | 7:00 PM ET

    The biotech company's top executive discusses its product line, future prospects and the biotech industry in general.

  • FDA Hearing on Avastin     Tuesday, 28 Jun 2011 | 6:47 AM ET

    The FDA begins hearings on the effectiveness of Genentech's breast cancer drug reports CNBC's Hampton Pearson.